Katia Bassett
Head, CDx Development Genentech
Seminars
Thursday 25th September 2025
The Journey of an FDA-Approved CDx for Rare Fusions: Rozlytrek CDx Case Study
8:10 am
- Genentech’s first FDA-approved tumor-agnostic medicine designed to target both ROS1 and NTRKÂ
- Roche/Genentech and Foundation Medicine (FMI) CDx collaboration: Comprehensive genomic testing is critical to identify patients with rare gene fusionsÂ
- Understanding of the techniques for NTRK testing in clinical practiceÂ
